<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04174365</url>
  </required_header>
  <id_info>
    <org_study_id>331-201-00148</org_study_id>
    <nct_id>NCT04174365</nct_id>
  </id_info>
  <brief_title>Brexpiprazole in Treatment of Children and Adolescents With Irritability Associated With Autism Spectrum Disorder</brief_title>
  <acronym>Anchor</acronym>
  <official_title>A Phase 3, Multicenter, Randomized, Double-blind, Placebo Controlled Trial of Brexpiprazole in Treatment of Children and Adolescents With Irritability Associated With Autism Spectrum Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Otsuka Pharmaceutical Development &amp; Commercialization, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>H. Lundbeck A/S</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Otsuka Pharmaceutical Development &amp; Commercialization, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to find out about the potential benefits and safety of
      brexpiprazole in children and adolescent subjects, aged 5 to 17, with irritability associated
      with autism spectrum disorder.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 30, 2019</start_date>
  <completion_date type="Anticipated">February 23, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 23, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The mean change from baseline to Week 8 in the Aberrant Behavior Checklist- Irritability subscale score (ABC-I)</measure>
    <time_frame>From baseline to Week 8 visit</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The mean change from baseline to Week 8 in the Clinical Global Impression- Severity of Illness Scale (CGI-S) score pertaining to irritability</measure>
    <time_frame>From baseline to Week 8 visit</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Irritability Associated With Autism Spectrum Disorder (ASD)</condition>
  <arm_group>
    <arm_group_label>Brexpiprazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>No Intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Brexpiprazole</intervention_name>
    <description>Oral tablet; take once daily</description>
    <arm_group_label>Brexpiprazole</arm_group_label>
    <other_name>brexpiprazole, OPC-34712 and LuAF41156</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>No Intervention</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Primary DSM-5 diagnosis of Autism Spectrum Disorder

          -  ABC-I subscale score of ≥ 18

          -  CGI-S scale score pertaining to irritability ≥ 4

          -  Mental age of ≥ 2 years as determined by Investigator based upon school participation,
             social history or medical records

          -  Ability for parent/caregiver to follow all protocol procedures

          -  Able to swallow tablets

          -  Able to discontinue all prohibited concomitant medications to meet protocol required
             washouts prior to and during the trial period

        Key Exclusion Criteria:

          -  Primary diagnosis of bipolar I disorder, including any DSM-5 current diagnosis of
             bipolar II disorder, schizophrenia, schizoaffective disorder, major depressive
             episode, PTSD. ADHD maybe exclusionary if it is the primary disorder, or is not stable
             or adequately treated.

          -  current or historical diagnosis of Fragile-X Syndrome or Rett's Disorder

          -  history of neuroleptic malignant syndrome

          -  a significant risk of committing violent acts, serious self-harm, or suicide

          -  epilepsy, a history of seizures, or a history of severe head trauma or stroke, or have
             a history or current evidence of other unstable medical conditions

          -  current hypothyroidism or hyperthyroidism

          -  uncontrolled Type I or Type II diabetes

          -  uncontrolled hypertension or symptomatic hypotension, or orthostatic hypotension

          -  Weight &lt; 15 kg

          -  Previous exposure to brexpiprazole

          -  Sexually active males or females, who could become pregnant, not agreeing to practice
             2 different methods of birth control or remain abstinent during the trial and for 30
             days at the end of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>OPDC Call Center</last_name>
    <phone>1-844-687-8522</phone>
    <email>OtsukaRMReconciliation@rmpdc.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>For additional information regarding sites</name>
      <address>
        <city>Princeton</city>
        <state>New Jersey</state>
        <zip>08540</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>contact by phone or email</last_name>
      <phone>844-687-8522</phone>
      <email>OtsukaRMReconciliation@rmpdc.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 20, 2019</study_first_submitted>
  <study_first_submitted_qc>November 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 22, 2019</study_first_posted>
  <last_update_submitted>May 27, 2020</last_update_submitted>
  <last_update_submitted_qc>May 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Autism</keyword>
  <keyword>Irritability</keyword>
  <keyword>Autism Spectrum Disorder</keyword>
  <keyword>ASD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Autistic Disorder</mesh_term>
    <mesh_term>Autism Spectrum Disorder</mesh_term>
    <mesh_term>Child Development Disorders, Pervasive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brexpiprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

